Literature DB >> 32181901

A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).

Shengjie Dong1, Jiachen Sun2, Zhuo Mao3, Lu Wang4, Yi-Lin Lu5, Jiesen Li6,7.   

Abstract

During an outbreak of respiratory diseases including atypical pneumonia in Wuhan, a previously unknown β-coronavirus was detected in patients. The newly discovered coronavirus is similar to some β-coronaviruses found in bats but different from previously known SARS-CoV and MERS-CoV. High sequence identities and similarities between 2019-nCoV and SARS-CoV were found. In this study, we searched the homologous templates of all nonstructural and structural proteins of 2019-nCoV. Among the nonstructural proteins, the leader protein (nsp1), the papain-like protease (nsp3), the nsp4, the 3C-like protease (nsp5), the nsp7, the nsp8, the nsp9, the nsp10, the RNA-directed RNA polymerase (nsp12), the helicase (nsp13), the guanine-N7 methyltransferase (nsp14), the uridylate-specific endoribonuclease (nsp15), the 2'-O-methyltransferase (nsp16), and the ORF7a protein could be built on the basis of homology templates. Among the structural proteins, the spike protein (S-protein), the envelope protein (E-protein), and the nucleocapsid protein (N-protein) can be constructed based on the crystal structures of the proteins from SARS-CoV. It is known that PL-Pro, 3CL-Pro, and RdRp are important targets for design antiviral drugs against 2019-nCoV. And S protein is a critical target candidate for inhibitor screening or vaccine design against 2019-nCoV because coronavirus replication is initiated by the binding of S protein to cell surface receptors. It is believed that these proteins should be useful for further structure-based virtual screening and related computer-aided drug development and vaccine design.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  2019-nCoV; BLAST algorithm; CLUSTAL analysis; MERS-CoV; SARS-CoV; coronavirus; homology modeling; sequence alignment

Mesh:

Substances:

Year:  2020        PMID: 32181901      PMCID: PMC7228330          DOI: 10.1002/jmv.25768

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


INTRODUCTION

In the past two decades, the epidemics of the two betacoronaviruses, severe acute respiratory syndrome coronavirus (SARS‐CoV) and Middle East respiratory syndrome coronavirus (MERS‐CoV) have caused more than 10 000 cumulative cases. , Very recently, there have been thousands of pneumonia cases in Wuhan, China. These cases of pneumonia were found to be related to a large seafood and animal market in Wuhan, where local government agencies quickly adopted sanitation and disinfection measures. Now, it is known that these cases of pneumonia were caused by a novel betacoronavirus, that is, the 2019 novel coronavirus (2019‐nCoV). , , , , , , , , , Then, the genome sequence and amino acid sequences were originally released by several research groups from different countries. , , The genome of the newly discovered CoV consists of a single, positive‐stranded RNA that is about 30k nucleotides long. The overall genome organization of the newly discovered CoV is similar to that of other coronaviruses. The newly sequenced virus genome encodes the open reading frames (ORFs) common to all betacoronaviruses, containing ORF1ab that encodes several enzymatic proteins, the spike‐surface glycoprotein (S protein), the small envelope protein (E protein), the matrix protein (M protein), and the nucleocapsid protein (N protein), as well as several nonstructural accessory proteins. Currently, the specific primers and probes for detection 2019‐nCoV were synthesized and fabricated against the genetic targets such as ORF1ab and N gene region. According to the gene sequencing data, Wu et al, Tao et al, and Uehara et al initially resolved the primary sequences of ten critical proteins, that is, ORF1ab polyprotein, surface glycoprotein, ORF3a protein, envelope protein, membrane glycoprotein, ORF6 protein, ORF7a protein, ORF8 protein, nucleocapsid phosphoprotein, and ORF10 protein, and published them on National Center for Biotechnology Information (NCBI). Within the past several months, with the new coronavirus pneumonia becoming more and more serious, the domestic research team is urgently tackling the problem. In recent days, relevant basic research has made rapid progress. Xu et al showed that the 2019‐nCoV shared with the SARS/SARS‐like coronaviruses a common ancestor that resembles the bat coronavirus HKU9‐1. Their work also pointed to the important discovery that the RBD domain of the 2019‐nCoV S‐protein supports strong interaction with human ACE2 molecules despite its sequence diversity with SARS‐CoV S‐protein and thus the 2019‐nCoV poses a significant public health risk for human transmission via the S‐protein–ACE2 binding pathway. On this basis of the structure of 3CL hydrolase (Mpro) of 2019‐nCoV, the joint team integrated the strategy of virtual screening and enzymology test, focused on the drug screening for the marketed drugs, as well as the self‐built “database of high‐yield compounds” and “database of compounds from medicinal plants”, and quickly found 30 kinds of possible treatments for 2019‐nCoV drugs, active natural products, and traditional Chinese medicine. A joint research team from the structural pharmacology and pharmaceutical chemistry laboratory has been working on the current outbreak of 2019‐nCoV pneumonia and their results showed that papain‐like protease (PLP) encoded by coronavirus nsp3 played an important role in viral genome replication and escape from the antivirus natural immunity of the host. PLP not only has protein hydrolase activity but also has the activity of de ubiquitinase (DUB). PLP uses its protein hydrolase activity and DUB activity to evade the host's antiviral immune response and inhibit the expression of interferon through a series of molecular mechanisms. It is another enzyme besides the coronavirus 3CL hydrolase, which are important proteins necessary for human infection. To find the potential drugs to inhibit the 2019‐nCoV coronavirus, the research team found that the 2019‐nCoV PLP sequence has 86% amino acid homology with SARS‐CoV PLP sequence. The research team built the protein structure of 2019‐nCoV PLP by using homology modeling method, defined its drug‐binding pocket, and screened the active molecules from the existing drug compound library of ZINC, the database of traditional Chinese medicine and natural products established by their own laboratory by using the computer‐aided structure‐based virtual screening method. Then, 33 potential inhibitors of 2019‐nCoV PLP were selected and expected to have possible anti‐2019‐nCoV activity. Several scientists speculated that Remdesivir may help fight the new coronavirus. The genetic material of the RNA virus is RNA (RNA ribonucleic acid). For the replication of the RNA virus genome, most of them need intermediate synthesis, which requires virus‐specific polymerase (RNA dependent RNA polymerase, RdRp, or RNA dependent DNA polymerase, RdDp). These polymerases are ideal targets for the design of antiviral drugs. Remdesivir works by interfering with RdRp. It is a precursor drug of adenosine analog. After triphosphate in vivo, it is incorporated into the newly synthesized RNA chain of the virus as a substrate, and then the synthesis of the virus genome is interrupted. , , , , It can be predicted that the research results of computational biology and bioinformatics will play an important role in the process of resistance to new coronavirus. , Realization and prediction of these structural and nonstructural proteins from 2019‐nCoV should be used by more scientific and technological workers, especially those engaged in drug research and development. Using the observed and achieved three‐dimensional models of these structural and nonstructural proteins, the screening of potential drugs against 2019‐nCoV could be carried out. In this study, using the amino acid sequences released on NCBI, we try to clarify the closest sequences and identify the most suitable template existed for homology modeling of several crucial proteins of 2019‐nCoV. This study would be beneficial to the next drug screening research.

MATERIALS, METHODS, AND PROCEDURES

Computational tools

The Basic Local Alignment Search Tool (BLAST) could find regions of local similarity between sequences. , , , , , The program compares nucleotide or protein sequences to sequence databases and calculates the statistical significance of matches. The maximum number of aligned sequences to display was set to 100. The expected number of chance matches in a random model was set to 10. The length of the seed that initiates an alignment was set to 6. SWISS‐MODEL is a fully automated protein structure homology‐modeling server, accessible via the ExPASy web server or from the program DeepView (Swiss Pdb‐Viewer). , , , The purpose of this server is to make protein modeling accessible to all life science researchers worldwide. Building a homology model comprises four main steps: identification of structural template(s), alignment of the target sequence and template structure(s), model‐building, and model quality evaluation. Clustal Omega is the latest addition to the Clustal family. , Clustal Omega is a multiple sequence alignment program that uses seeded guide trees and HMM profile‐profile techniques to generate alignments between three or more sequences. It produces biologically meaningful multiple sequence alignments of divergent sequences. In this study, using three popular online tools, that is, BLAST, SWISS‐MODEL, and Clustal Omega, we performed sequence alignment investigations on these 10 primary sequences of 2019‐nCoV.

Experimental procedures

The structures of the proteins from ORF1ab currently published on RCSB Protein Data Bank (PDB) and yet recommended by Protein Information Resource (PIR) were summarized in Table S1. To construct the proteins from ORF1ab, we distinguished the sequences related to the crystallized structures of the proteins from ORF1ab. After careful evaluation and screening, we compared the sequence of 2GDT, 2GRI, 2ACF, 2JZF, 2FE8, 2K87, 1Q2W, 2AHM, 6NUR, 1QZ8, 5C8S, 6JYT, 2H85, and 2XYQ with the whole sequence of 2019‐nCoV ORF1ab using Clustal Omega. After performing sequence alignment, we identified the sequences associated with these PDB files. Then, we searched for the template proteins of these specific sequences using SWISS‐MODEL. For proteins from 2019‐nCoV other than ORF1ab, we directly searched for the template proteins of their sequences using SWISS‐MODEL.

RESULTS AND DISCUSSION

Sequence alignment of ORF1ab among 2019‐nCoV, SARS‐CoV, and MERS‐CoV

According to BLAST analysis, the sequence identity of ORF1ab protein between 2019‐nCoV and SARS‐CoV is more than 90% with the query cover of about 100% while the sequence identity of ORF1ab protein between 2019‐nCoV and MERS‐CoV is less than 60% with the query cover of about 98%, which proves that the 2019‐nCoV shared a better sequence homology toward the sequences of SARS‐CoV than that of MERS‐CoV, which is consistent with previous research results. Using the Clustal Omega, the sequence alignment of 2019‐nCoV and SARS‐CoV, 2019‐nCoV and MERS‐CoV was carried out (see Figures S1 and S2).

Homology modeling of the proteins encoded by ORF1ab

Coronavirus family members are important pathogens of many domestic animals, pets, including human beings, causing a variety of acute and chronic diseases. Coronavirus has a large genome RNA, 27 to 32 kb in length, encoding structural proteins, nonstructural proteins, and some auxiliary proteins. The nonstructural protein of coronavirus is hydrolyzed from the virus‐encoded polyprotein 1ab. These nonstructural proteins are important functional proteins of coronavirus, which are involved in the regulation of viral genome RNA replication and subgenomic RNA transcription, or involved in genome replication and transcription as transcription/replication complexes, and involved in infection of the host. It is known that the Replicase polyprotein 1ab (alternative name: ORF1ab polyprotein) could be cleaved into the following 15 chains: (1) Host translation inhibitor nsp1 (alternative names: Leader protein, nsp1), (2) Nonstructural protein 2 (alternative names: p65 homolog, nsp2), (3) Papain‐like proteinase (alternative names: PL‐Pro, Nonstructural protein 3, nsp3), (4) Nonstructural protein 4 (alternative name: nsp4), (5) 3C‐like proteinase (alternative names: 3CL‐Pro, nsp5), (6) Nonstructural protein 6 (alternative name: nsp6), (7) Nonstructural protein 7 (alternative name: nsp7), (8) Nonstructural protein 8 (alternative name: nsp8), (9) Nonstructural protein 9 (alternative name: nsp9), (10) Nonstructural protein 10 (alternative names: Growth factor‐like peptide, GFL, nsp10), (11) RNA‐directed RNA polymerase (alternative names: RdRp, nsp12), (12) Helicase (alternative names: Hel, nsp13), (13) Guanine‐N7 methyltransferase (alternative names: ExoN, nsp14), (14) Uridylate‐specific endoribonuclease (alternative names: NendoU, nsp15), and (15) 2’‐O‐methyltransferase (alternative name: nsp16). Here, we summarized the main findings mentioned in this section on the structure prediction of the proteins encoded by ORF1ab using the homology modeling method in Table 1. Specific measures and experimental details to obtain these valuable results are disclosed in the supplementary documents (also see Figures S3‐S62). According to the recent reports mentioned in chapter 1, the PL‐Pro, 3CL‐Pro, and RdRp should be important targets for design antiviral drugs against 2019‐nCoV. In addition, the cartoons of the proteins modeled in this section are shown in Figure 1. We found that the main color of these ribbons is composed of blue, indicating that the structures of these proteins are stretched to a considerable extent.
Table 1

Initial reference templates, final recommended templates, and sequence identities information for homology modeling of the ORF1ab related proteins

Target descriptionInitial reference templateFinal recommended templateSequence identity
Leader protein nsp12GDT_A2HSX_A86.09%
Papain‐like protease nsp32GRI_A2IDY_A79.28%
Papain‐like protease nsp32ACF_A2ACF_A73.37%
Papain‐like protease nsp32JZF_A2WCT_A79.33%
Papain‐like protease nsp32KAF_A2KAF_A72.31%
Papain‐like protease nsp32FE8_A5TI6_A82.86%
Papain‐like protease nsp32K87_A2K87_A81.74%
Nonstructural protein 43VCB_A3VCB_A60.23%
3C‐like protease nsp51Q2W_A5B6O_A94.53%
Nonstructural protein 72AHM_A2AHM_A98.80%
Nonstructural protein 82AHM_G2AHM_G97.47%
Nonstructural protein 91QZ8_A1UW7_A97.35%
Nonstructural protein 105C8S_A5C8S_A98.50%
RNA‐directed RNA polymerase nsp126NUR_A6NUR_A96.35%
Helicase nsp136JYT_A6JYT_A99.83%
Guanine‐N7 methyltransferase nsp145C8S_B5C8S_B95.07%
Uridylate‐specific endoribonuclease nsp152H85_A2H85_A88.15%
2'‐O‐methyltransferase nsp162XYQ_A3R24_A93.24%
Figure 1

Cartoon displayed models of ORF1ab related proteins constructed based on (A) 2HSX_A, (B) 2IDY_A, (C) 2ACF_A, (D) 2WCT_A, (E) 2KAF_A, (F) 5TI6_A, (G) 2K87_A, (H) 3VCB_A, (I) 5B6O_A, (J) 2AHM_A, (K) 2AHM_G, (L) 1UW7_A, (M) 5C8S_A, (N) 6NUR_A, (O) 6JYT_A, (P) 5C8S_B, (Q) 2H85_A, and (R) 3R24_A

Initial reference templates, final recommended templates, and sequence identities information for homology modeling of the ORF1ab related proteins Cartoon displayed models of ORF1ab related proteins constructed based on (A) 2HSX_A, (B) 2IDY_A, (C) 2ACF_A, (D) 2WCT_A, (E) 2KAF_A, (F) 5TI6_A, (G) 2K87_A, (H) 3VCB_A, (I) 5B6O_A, (J) 2AHM_A, (K) 2AHM_G, (L) 1UW7_A, (M) 5C8S_A, (N) 6NUR_A, (O) 6JYT_A, (P) 5C8S_B, (Q) 2H85_A, and (R) 3R24_A

Homology modeling of the other proteins from 2019‐nCoV

The diameter of coronavirus is 80 to 120 nm. Under the electron microscope, the surface of virus particles has a club like protrusion, which is composed of spike protein (S protein). The envelope of the virus consists of membrane glycoprotein (M protein), which is embedded in the envelope of the virus through three transmembrane domains. In addition, a small amount of small transmembrane protein envelope protein (E protein) also appeared in the envelope. Finally, the nucleocapsid protein (N protein) binds to the RNA genome in the form of beads, forming a helically symmetric nucleocapsid. Here, we explored the rationality and feasibility of the homology modeling of other proteins. According to BLAST search results, it is found that SARS spike glycoprotein is a good template for constructing 2019‐nCoV surface glycoprotein. We also found that MERS spike glycoprotein is similar to 2019‐nCoV surface glycoprotein. But the homology of SARS S protein (PDB ID: 6ACC_A) and 2019‐nCoV S protein is about 76%, and the query coverage rate is 95%; the homology of MERS S protein (PDB ID: 5X59) and 2019‐nCoV S protein is about 34%, and the query coverage rate is 74% (see Figures S63 and S64). Using SWISS‐MODEL, 6ACD_C can be used as a potential template for modeling 2019‐nCoV S protein (see Figure S65). Then, the homology modeling of S protein could be realized (see Figure S66). Next, we try to perform the homology modeling of ORF3a protein. Nevertheless, although 2019‐nCoV ORF3a protein and SARS‐CoV ORF3a protein are highly homologous (see Figure S67), the crystal structure of this protein is unknown up to now (see Figure S68). Fortunately, the crystal structure of the template protein for modeling 2019‐nCoV E protein is realized experimentally (see Figure S69). Using SWISS‐MODEL, the template was found successfully (see Figure S70). The sequence identity is more than 90% (see Figure S71). Regretfully, the crystal structure of the template protein for modeling membrane glycoprotein and ORF6 protein is deficient (see Figures S72‐S75). Hopefully, the structure of the template protein of ORF7a protein has been identified experimentally (see Figure S76). Using SWISS‐MODEL, the template was found successfully (see Figure S77). The sequence identity is more than 90% (see Figure S78). Currently, there is no suitable template protein for the homology modeling of ORF8 protein (see Figures S79 and S80). Then, we tried to model the structure of the N protein. We found that the N protein would be divided into two parts and the two parts need to be modeled independently (see Figure S81). The sequence identity is more than 90% (see Figures S82 and S83). ORF10 protein is a short peptide, and there is no template available at present. Here, we summarized the main findings mentioned in this section on the structure prediction of the other proteins from 2019‐nCoV using the homology modeling method in Table 2. Coronavirus replication is initiated by the binding of S protein to cell surface receptors. S protein consists of two functional subunits. S1 (globule) is used for receptor binding and S2 (stem) is used for membrane fusion. The specific interaction between S1 and homologous receptors can trigger the conformational change of the S2 subunit, which leads to the fusion of virus envelope and cell membrane and release of nucleocapsid into the cytoplasm. Receptor binding largely determines the host range and histotropism of coronavirus. Thus, the S protein should be a critical candidate for drug screening or vaccine design against 2019‐nCoV. , In addition, the cartoons of the proteins modeled in this section are shown in Figure 2. We found that the main color of these ribbons is composed of red, demonstrating that there are some squeezing and collision between the atoms in these structures to some degree. Consequently, before these models can be used as targets for computer‐aided drug design, conformation optimization based on molecular mechanics or molecular dynamics should be performed sufficiently.
Table 2

Recommended templates and sequence identities of S protein, E protein, ORF7a protein, and N protein

Target descriptionRecommended templateSequence identity
S protein6ACD_A76.47%
E protein5X29_A91.38%
ORF7a1YO4_A91.57%
N protein1SSK_A92.37%
N protein2JW8_A95.76%
Figure 2

Cartoon displayed models of proteins constructed based on (A) 6ACD_A, (B) 5X29_A, (C) 1YO4_A, (D) 1SSK_A, and (E) 2JW8_A

Recommended templates and sequence identities of S protein, E protein, ORF7a protein, and N protein Cartoon displayed models of proteins constructed based on (A) 6ACD_A, (B) 5X29_A, (C) 1YO4_A, (D) 1SSK_A, and (E) 2JW8_A

SUMMARY AND CONCLUSIONS

COVID‐2019 pneumonia continues to spread on a global scale. , , , , When a frightening new virus appears, in addition to developing new drugs and vaccines, scientists will also consider trying existing antiviral drugs, which may lead to good results. During the outbreak of SARS in 2003, scientists used protease inhibitors to reduce the viral load of patients, and protease inhibitors were also proved effective for MERS. Today's new coronaviruses, like SARS and MERS viruses, are all coronaviruses. Therefore, scientists speculate that protease inhibitors can reduce a load of new coronaviruses in patients. Protease inhibitor is a kind of drug targeting protease to treat AIDS. At present, the National Health Commission has recommended that anti‐AIDS drugs can be included in the trial. Chinese scientists are testing the anti‐HIV drug program to see if it is effective against the new coronavirus. Several research groups from different countries reported their sequencing results and showed that this newly sequenced virus genome encodes the open reading frames (ORFs) common to all β‐coronaviruses, including ORF1ab that encodes many enzymatic proteins, the spike‐surface glycoprotein (S‐protein), the small envelope protein (E‐protein), the matrix protein (M‐protein), and the nucleocapsid protein (N‐protein), as well as several nonstructural proteins. 2019‐nCoV shared a better sequence homology toward the sequences of SARS‐CoV than that of MERS‐CoV. We demonstrated that it is likely that they share considerable sequence consistent with the SARS or SARS‐like coronaviruses, which is in accordance with the previously published work. High sequence identities and similarities between 2019‐nCoV and SARS‐CoV were found. We searched the homologous templates of all structural and nonstructural proteins of 2019‐nCoV. These protein models should be useful for molecular docking investigations and molecular dynamics simulations. Moreover, these resulting structures would be meaningful for further structure‐based virtual screening and related computer‐aided drug design.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

SD and YLL designed the project. SD and JL prepared the manuscript. SD and JS performed the calculations. SD and ZM analyzed the data. SD and LW discussed the results. Supporting information Click here for additional data file.
  41 in total

1.  Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective.

Authors:  Nicolas Guex; Manuel C Peitsch; Torsten Schwede
Journal:  Electrophoresis       Date:  2009-06       Impact factor: 3.535

2.  Medical Journals and the 2019-nCoV Outbreak.

Authors:  Eric J Rubin; Lindsey R Baden; Stephen Morrissey; Edward W Campion
Journal:  N Engl J Med       Date:  2020-01-27       Impact factor: 91.245

3.  Coronavirus Infections-More Than Just the Common Cold.

Authors:  Catharine I Paules; Hilary D Marston; Anthony S Fauci
Journal:  JAMA       Date:  2020-02-25       Impact factor: 56.272

4.  Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge.

Authors:  Michael K Lo; Friederike Feldmann; Joy M Gary; Robert Jordan; Roy Bannister; Jacqueline Cronin; Nishi R Patel; John D Klena; Stuart T Nichol; Tomas Cihlar; Sherif R Zaki; Heinz Feldmann; Christina F Spiropoulou; Emmie de Wit
Journal:  Sci Transl Med       Date:  2019-05-29       Impact factor: 17.956

5.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.

Authors:  Timothy P Sheahan; Amy C Sims; Rachel L Graham; Vineet D Menachery; Lisa E Gralinski; James B Case; Sarah R Leist; Krzysztof Pyrc; Joy Y Feng; Iva Trantcheva; Roy Bannister; Yeojin Park; Darius Babusis; Michael O Clarke; Richard L Mackman; Jamie E Spahn; Christopher A Palmiotti; Dustin Siegel; Adrian S Ray; Tomas Cihlar; Robert Jordan; Mark R Denison; Ralph S Baric
Journal:  Sci Transl Med       Date:  2017-06-28       Impact factor: 17.956

6.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.

Authors:  Xintian Xu; Ping Chen; Jingfang Wang; Jiannan Feng; Hui Zhou; Xuan Li; Wu Zhong; Pei Hao
Journal:  Sci China Life Sci       Date:  2020-01-21       Impact factor: 6.038

7.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  A novel coronavirus outbreak of global health concern.

Authors:  Chen Wang; Peter W Horby; Frederick G Hayden; George F Gao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

9.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

10.  COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis.

Authors:  Silvia Angeletti; Domenico Benvenuto; Martina Bianchi; Marta Giovanetti; Stefano Pascarella; Massimo Ciccozzi
Journal:  J Med Virol       Date:  2020-02-28       Impact factor: 2.327

View more
  34 in total

Review 1.  Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Limei Cheng; Jaclyn Frishcosy; Yuta Huzumi; Yuchi Qiu; Tom Schluckbier; Xiaoqi Wei; Guo-Wei Wei
Journal:  Chem Rev       Date:  2022-05-20       Impact factor: 72.087

2.  A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection.

Authors:  Joseph R McGill; H A Daniel Lagassé; Nancy Hernandez; Louis Hopkins; Wojciech Jankowski; Quinn McCormick; Vijaya Simhadri; Basil Golding; Zuben E Sauna
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

3.  Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529.

Authors:  Jency Roshni; R Vaishali; K S Ganesh; N Dharani; Khalid J Alzahrani; Hamsa Jameel Banjer; Ali H Alghamdi; Abdulrahman Theyab; Shiek Ssj Ahmed; Shankargouda Patil
Journal:  J Infect Public Health       Date:  2022-05-13       Impact factor: 7.537

Review 4.  p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics).

Authors:  Daniela Milani; Lorenzo Caruso; Enrico Zauli; Adi Mohammed Al Owaifeer; Paola Secchiero; Giorgio Zauli; Donato Gemmati; Veronica Tisato
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

5.  Pharmacological approaches to the treatment of COVID-19 patients.

Authors:  Lawrence C Sowers; Lucas S Blanton; Scott C Weaver; Randall J Urban; Charles P Mouton
Journal:  J Transl Sci       Date:  2020-04-17

6.  A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex.

Authors:  Aliakbar Khalili Yazdi; Fengling Li; Kanchan Devkota; Sumera Perveen; Pegah Ghiabi; Taraneh Hajian; Albina Bolotokova; Masoud Vedadi
Journal:  SLAS Discov       Date:  2021-04-19       Impact factor: 3.341

7.  Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.

Authors:  Renata Kasprzyk; Tomasz J Spiewla; Miroslaw Smietanski; Sebastian Golojuch; Laura Vangeel; Steven De Jonghe; Dirk Jochmans; Johan Neyts; Joanna Kowalska; Jacek Jemielity
Journal:  Antiviral Res       Date:  2021-07-23       Impact factor: 5.970

8.  A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).

Authors:  Shengjie Dong; Jiachen Sun; Zhuo Mao; Lu Wang; Yi-Lin Lu; Jiesen Li
Journal:  J Med Virol       Date:  2020-03-29       Impact factor: 2.327

9.  Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses.

Authors:  Resmi Ravindran; Cindy McReynolds; Jun Yang; Bruce D Hammock; Aamer Ikram; Amna Ali; Adnan Bashir; Tanzeel Zohra; W L William Chang; Dennis J Hartigan-O'Connor; Hooman H Rashidi; Imran H Khan
Journal:  PLoS One       Date:  2021-07-09       Impact factor: 3.240

10.  Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein.

Authors:  Mushtaq Hussain; Nusrat Jabeen; Fozia Raza; Sanya Shabbir; Ayesha A Baig; Anusha Amanullah; Basma Aziz
Journal:  J Med Virol       Date:  2020-04-15       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.